

Luca Miele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8839108/publications.pdf>

Version: 2024-02-01

173
papers

8,926
citations

44069

48
h-index

48315

88
g-index

178
all docs

178
docs citations

178
times ranked

12598
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2009, 49, 1877-1887.	7.3	1,138
2	Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. <i>Digestive and Liver Disease</i> , 2015, 47, 997-1006.	0.9	368
3	The Liver May Act as a Firewall Mediating Mutualism Between the Host and Its Gut Commensal Microbiota. <i>Science Translational Medicine</i> , 2014, 6, 237ra66.	12.4	365
4	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <i>Digestive and Liver Disease</i> , 2017, 49, 471-483.	0.9	254
5	Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. <i>Gut</i> , 2005, 54, 411-418.	12.1	215
6	Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. <i>Journal of Hepatology</i> , 2009, 51, 778-786.	3.7	209
7	Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. <i>Free Radical Biology and Medicine</i> , 2012, 52, 1658-1665.	2.9	201
8	NAFLD in children: new genes, new diagnostic modalities and new drugs. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 517-530.	17.8	199
9	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017, 7, 4492.	3.3	193
10	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021, 74, 775-782.	3.7	193
11	The Kruppel-Like Factor 6 Genotype Is Associated With Fibrosis in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2008, 135, 282-291.e1.	1.3	177
12	Liver Transplantation in Alcoholic Patients: Impact of an Alcohol Addiction Unit Within a Liver Transplant Center. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 1601-1608.	2.4	156
13	A 360-degree overview of paediatric NAFLD: Recent insights. <i>Journal of Hepatology</i> , 2013, 58, 1218-1229.	3.7	154
14	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	3.7	149
15	Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. <i>Digestive and Liver Disease</i> , 2014, 46, 556-560.	0.9	142
16	Pathophysiology of Non Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2082.	4.1	126
17	Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk. <i>Current Cardiology Reports</i> , 2015, 17, 120.	2.9	125
18	Nonalcoholic Fatty Liver Disease as a Contributor to Hypercoagulation and Thrombophilia in the Metabolic Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 277-287.	2.7	123

#	ARTICLE	IF	CITATIONS
19	Hepatic Mitochondrial Beta-Oxidation in Patients With Nonalcoholic Steatohepatitis Assessed by ¹³ C-Octanoate Breath Test. <i>American Journal of Gastroenterology</i> , 2003, 98, 2335-2336.	0.4	115
20	Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2014, 9, e87523.	2.5	112
21	Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. <i>Journal of Hepatology</i> , 2011, 54, 1244-1249.	3.7	107
22	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 626-634.	8.1	103
23	Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. <i>World Journal of Gastroenterology</i> , 2019, 25, 4814-4834.	3.3	101
24	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 786-794.	3.7	100
25	High efficacy of 1-week doxycycline and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 789-795.	3.7	98
26	Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target. <i>Current Pharmaceutical Design</i> , 2013, 19, 5314-5324.	1.9	98
27	Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 369-384.	2.6	96
28	Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2358-2363.	3.8	96
29	Breath testing for human liver function assessment. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1977-1996.	3.7	94
30	Tumor necrosis factor- α inhibitors and chronic hepatitis C: A comprehensive literature review. <i>World Journal of Gastroenterology</i> , 2013, 19, 7867.	3.3	90
31	Balancing Donor and Recipient Risk Factors in Liver Transplantation: The Value of D-MELD With Particular Reference to HCV Recipients. <i>American Journal of Transplantation</i> , 2011, 11, 2724-2736.	4.7	86
32	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019, 9, 3682.	3.3	85
33	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016, 64, 34-46.	7.3	83
34	Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2 positive patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1060-1068.	3.7	76
35	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020, 98, 106175.	1.8	71
36	A polymorphism in the Irisin-encoding gene (FND5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. <i>Journal of Hepatology</i> , 2019, 70, 494-500.	3.7	67

#	ARTICLE	IF	CITATIONS
37	A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. <i>BMC Cancer</i> , 2009, 9, 271.	2.6	65
38	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016, 64, 390-398.	3.7	64
39	Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows. <i>World Journal of Gastroenterology</i> , 2018, 24, 2582-2595.	3.3	59
40	SARS-CoV2 RNA detection in a pancreatic pseudocyst sample. <i>Pancreatology</i> , 2020, 20, 1011-1012.	1.1	59
41	Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. <i>Nutrients</i> , 2019, 11, 2971.	4.1	57
42	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016, 48, 333-342.	0.9	56
43	Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. <i>Digestive and Liver Disease</i> , 2004, 36, 398-405.	0.9	56
44	Glucokinase links KrÄppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012, 55, 1083-1093.	7.3	55
45	Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2. <i>Cell Death and Differentiation</i> , 2017, 24, 889-902.	11.2	53
46	Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 1037-46.	2.4	52
47	Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2012, 7, e41183.	2.5	51
48	The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1225.	4.1	50
49	Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 509-520.	3.3	50
50	Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGFÄ levels. <i>Clinical Endocrinology</i> , 2012, 77, 531-536.	2.4	49
51	Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target. <i>Current Pharmaceutical Design</i> , 2013, 19, 5314-24.	1.9	49
52	Ä-Klotho gene variation is associated with liver damage in children with NAFLD. <i>Journal of Hepatology</i> , 2020, 72, 411-419.	3.7	48
53	Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. <i>Clinical Endocrinology</i> , 2011, 75, 520-527.	2.4	46
54	Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?. <i>British Journal of Dermatology</i> , 2018, 179, 16-29.	1.5	46

#	ARTICLE	IF	CITATIONS
55	Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib. <i>Current Drug Targets</i> , 2016, 17, 783-799.	2.1	46
56	TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 759-788.	4.5	44
57	Acute hepatitis caused by a natural lipid-lowering product: When "alternative" medicine is no "alternative" at all. <i>Journal of Hepatology</i> , 2009, 50, 1273-1277.	3.7	43
58	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017, 6, 1930-1940.	2.8	43
59	Acute Cholestatic Hepatitis Associated with Celecoxib. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1887-1889.	1.9	41
60	Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). <i>Translational Research</i> , 2007, 149, 114-125.	5.0	41
61	Abdominal Angina. <i>American Journal of the Medical Sciences</i> , 2009, 338, 389-395.	1.1	41
62	A case-control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver disease. <i>Genes and Nutrition</i> , 2014, 9, 383.	2.5	41
63	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 1105-1114.	0.9	41
64	Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-5.	1.5	40
65	COVID-19 and intestinal inflammation: Role of fecal calprotectin. <i>Digestive and Liver Disease</i> , 2020, 52, 1231-1233.	0.9	40
66	Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6485.	4.1	40
67	Role of diffusion-weighted imaging, apparent diffusion coefficient and correlation with hepatobiliary phase findings in the differentiation of hepatocellular carcinoma from dysplastic nodules in cirrhotic liver. <i>European Radiology</i> , 2015, 25, 1087-1096.	4.5	39
68	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2018, 2, 666-675.	4.3	38
69	Rare ATG7 genetic variants predispose patients to severe fatty liver disease. <i>Journal of Hepatology</i> , 2022, 77, 596-606.	3.7	38
70	Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. <i>Translational Research</i> , 2009, 154, 194-201.	5.0	37
71	Assessment of neurological manifestations in hospitalized patients with COVID-19. <i>European Journal of Neurology</i> , 2020, 27, 2322-2328.	3.3	36
72	Gut microbiota, obesity and metabolic disorders. <i>Minerva Gastroenterology</i> , 2017, 63, 337-344.	0.5	34

#	ARTICLE	IF	CITATIONS
73	Anisakis infestation: a case of acute abdomen mimicking Crohn's disease and eosinophilic gastroenteritis. <i>Digestive and Liver Disease</i> , 2005, 37, 62-64.	0.9	33
74	Copper/MYC/CTR1 interplay: a dangerous relationship in hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 9325-9343.	1.8	30
75	Role of the "Immersation Technique" in Diagnosing Celiac Disease With Villous Atrophy Limited to the Duodenal Bulb. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 571-575.	2.2	27
76	Enhanced Liver Fibrosis Test as a Reliable Tool for Assessing Fibrosis in Nonalcoholic Fatty Liver Disease in a Clinical Setting. <i>International Journal of Biological Markers</i> , 2017, 32, 397-402.	1.8	27
77	Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics. <i>Cancers</i> , 2019, 11, 1568.	3.7	27
78	A case of variant angina in a patient under chronic treatment with sorafenib. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 476-480.	27.6	26
79	Is coeliac disease a confounding factor in the diagnosis of NASH? Reply. <i>Gut</i> , 2001, 49, 596-596.	12.1	24
80	Understanding the association between developing a fatty liver and subsequent cardio-metabolic complications. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1243-1245.	3.0	23
81	Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 112, 154355.	3.4	23
82	Correlates of HCV seropositivity among familial contacts of HCV positive patients. <i>BMC Public Health</i> , 2006, 6, 237.	2.9	21
83	Liver toxicity of rosuvastatin therapy. <i>World Journal of Gastroenterology</i> , 2007, 13, 1286.	3.3	21
84	A case-control study on the effects of the apolipoprotein E genotypes in nonalcoholic fatty liver disease. <i>Molecular Biology Reports</i> , 2012, 39, 7381-7388.	2.3	21
85	Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging. <i>Abdominal Imaging</i> , 2013, 38, 736-744.	2.0	21
86	A phase II study of sunitinib in advanced hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2013, 45, 692-698.	0.9	21
87	Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. <i>Translational Research</i> , 2021, 231, 24-38.	5.0	21
88	When Was Celiac Disease Born?. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 502-503.	2.2	20
89	Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD). <i>Clinical Epigenetics</i> , 2020, 12, 126.	4.1	20
90	Fatty liver and drugs: the two sides of the same coin. <i>European Review for Medical and Pharmacological Sciences</i> , 2017, 21, 86-94.	0.7	20

#	ARTICLE	IF	CITATIONS
91	Impairment of Recent Thymic Emigrants in HCV Infection. <i>International Journal of Immunopathology and Pharmacology</i> , 2005, 18, 723-728.	2.1	19
92	Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study. <i>BMC Infectious Diseases</i> , 2018, 18, 223.	2.9	19
93	Intrafamilial transmission of hepatitis C virus in Italy: a systematic review. <i>Journal of Epidemiology and Community Health</i> , 2010, 64, 843-848.	3.7	18
94	Hepatitis C in the elderly: A multicentre cross-sectional study by the Italian Association for the Study of the Liver. <i>Digestive and Liver Disease</i> , 2012, 44, 674-680.	0.9	17
95	The Effect of CYP, GST, and SULT Polymorphisms and Their Interaction with Smoking on the Risk of Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2015, 2015, 1-7.	1.9	17
96	Elevated Hemoglobin Level Is Associated With Advanced Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 65, 150-155.	1.8	17
97	COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12977.	2.7	17
98	Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: Serum sodium predicts survival. <i>World Journal of Gastroenterology</i> , 2014, 20, 8158.	3.3	17
99	Non-alcoholic steatohepatitis induced by carbamazepine and variegate porphyria. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 973-975.	1.6	16
100	Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms. <i>Digestive and Liver Disease</i> , 2012, 44, 1032-1036.	0.9	16
101	The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients. <i>Cancers</i> , 2021, 13, 1783.	3.7	16
102	Impairment of splenic IgM-memory but not switched-memory B cells in a patient with celiac disease and splenic atrophy. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 1461-1463.	2.9	15
103	Socio-demographic determinants of coinfections by HIV, hepatitis B and hepatitis C viruses in central Italian prisoners. <i>BMC Infectious Diseases</i> , 2007, 7, 100.	2.9	15
104	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	8.1	15
105	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1-16.	2.6	15
106	Anticholinergic syndrome due to 'Devil's herb': when risks come from the ancient time. <i>International Journal of Clinical Practice</i> , 2006, 60, 492-494.	1.7	14
107	Mild hepatitis at recommended doses of acetaminophen in patients with evidence of constitutionally enhanced cytochrome P450 system activity. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2008, 33, 315-320.	1.5	14
108	Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders. <i>Digestive and Liver Disease</i> , 2016, 48, 927-933.	0.9	14

#	ARTICLE	IF	CITATIONS
109	PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease. <i>Nutrients</i> , 2018, 10, 1239.	4.1	14
110	A Role for the Biological Clock in Liver Cancer. <i>Cancers</i> , 2019, 11, 1778.	3.7	14
111	Effect of Sildenafil on Diabetic Gastropathy. <i>Diabetes Care</i> , 2002, 25, 1888-1889.	8.6	12
112	High Prevalence and Gender-Related Differences of Gastrointestinal Manifestations in a Cohort of DM1 Patients: A Perspective, Cross-Sectional Study. <i>Frontiers in Neurology</i> , 2020, 11, 394.	2.4	12
113	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Digestive and Liver Disease</i> , 2022, 54, 170-182.	0.9	12
114	Cystic lymphangioma of the mesentery and hyposplenism in celiac disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 1026-1030.	1.6	11
115	Severe Cholestatic Hepatitis due to Temozolomide. <i>Medicine (United States)</i> , 2015, 94, e476.	1.0	11
116	The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation. <i>EBioMedicine</i> , 2021, 65, 103249.	6.1	11
117	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. <i>EBioMedicine</i> , 2021, 70, 103521.	6.1	11
118	Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival. <i>Hepato-Gastroenterology</i> , 2003, 50, 207-12.	0.5	11
119	Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients. <i>Digestive and Liver Disease</i> , 2018, 50, 938-943.	0.9	10
120	Liver Transplantation in Patients with Alcoholic Liver Disease: A Retrospective Study. <i>Alcohol and Alcoholism</i> , 2018, 53, 151-156.	1.6	10
121	Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020, 1865, 158765.	2.4	10
122	Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. <i>Advanced Science</i> , 2021, 8, 2004168.	11.2	10
123	Mediterranean diet and the prevention of non-alcoholic fatty liver disease: results from a case-control study. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 7391-7398.	0.7	10
124	Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. <i>Internal and Emergency Medicine</i> , 2016, 11, 3-10.	2.0	9
125	Serum alkaline phosphatase, a risk factor for non-alcoholic fatty liver, but only for women in their 30s and 40s: evidence from a large cohort study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 1-8.	3.0	9
126	Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia. <i>Journal of Immunological Methods</i> , 2020, 476, 112687.	1.4	9

#	ARTICLE	IF	CITATIONS
127	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 1289-1292.	0.4	9
128	Acute HEV hepatitis: clinical and laboratory diagnosis. <i>European Review for Medical and Pharmacological Sciences</i> , 2019, 23, 764-770.	0.7	9
129	IgG cryoglobulinemia. <i>European Review for Medical and Pharmacological Sciences</i> , 2018, 22, 6057-6062.	0.7	9
130	Severe venoocclusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of venoocclusive disease. <i>Clinical Transplantation</i> , 2008, 22, 837-841.	1.6	8
131	The NAFL Risk Score: A simple scoring model to predict 4-y risk for non-alcoholic fatty liver. <i>Clinica Chimica Acta</i> , 2017, 468, 17-24.	1.1	8
132	Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients. <i>Digestive and Liver Disease</i> , 2018, 50, 156-162.	0.9	7
133	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018, 46, 607-615.	4.7	7
134	Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 2103-2110.	2.6	7
135	The role of elastography in non-alcoholic fatty liver disease. <i>Minerva Gastroenterology</i> , 2021, 67, 164-170.	0.5	7
136	Treatment of early stage chronic hepatitis C virus infection. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 519-524.	3.1	6
137	Clinical characteristics of metabolic associated fatty liver disease (MAFLD) in subjects with myotonic dystrophy type 1 (DM1). <i>Digestive and Liver Disease</i> , 2021, 53, 1451-1457.	0.9	6
138	COVID-19, adaptative immune response and metabolic-associated liver disease. <i>Liver International</i> , 2021, 41, 2560-2577.	3.9	6
139	AISF position paper on HCV in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2019, 51, 10-23.	0.9	5
140	Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm. <i>World Journal of Gastroenterology</i> , 2011, 17, 3126-32.	3.3	5
141	Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study. <i>Journal of Viral Hepatitis</i> , 2010, 17, 427-434.	2.0	4
142	A case of esomeprazole-induced transient diabetes and hepatitis: the role of liver inflammation in the pathogenesis of insulin resistance. <i>Acta Diabetologica</i> , 2014, 51, 151-153.	2.5	4
143	Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression. <i>Rheumatology</i> , 2021, 60, 4418-4427.	1.9	4
144	Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target. <i>Current Pharmaceutical Design</i> , 2013, 19, 5314-5324.	1.9	4

#	ARTICLE	IF	CITATIONS
145	Evaluation of recent thymic emigrants (TREC _s) in patients affected by HCV chronic hepatitis. <i>Journal of Hepatology</i> , 2002, 36, 222.	3.7	3
146	Corrigendum to "Acute hepatitis caused by a natural lipid-lowering product: When "alternative" medicine is no "alternative" at all" [Hepatology 50 (2009) 1273-1277]. <i>Journal of Hepatology</i> , 2010, 52, 468.	3.7	3
147	Fat Deposits as Manifestation of Alcohol Use Disorder: Madelung's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, A26.	4.4	3
148	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. <i>PLoS ONE</i> , 2020, 15, e0243590.	2.5	3
149	Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation. <i>Cancers</i> , 2021, 13, 6337.	3.7	3
150	Hepatic mitochondrial beta-oxidation assessment in healthy subjects by sodium 13C-octanoate breath test. <i>Gastroenterology</i> , 2000, 118, A924-A925.	1.3	2
151	Watery stools and metabolic acidosis. <i>Internal and Emergency Medicine</i> , 2017, 12, 487-492.	2.0	2
152	Preventing liver fibrosis in patients with NAFLD and the road ahead. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 1081-1083.	3.0	2
153	Availability of a Web and Smartphone Application to Stratify the Risk of of Early Allograft Failure Requiring Liver Retransplantation. <i>Hepatology Communications</i> , 2022, 6, 247-248.	4.3	2
154	The Histone Variant MacroH2A1 Impacts Circadian Gene Expression and Cell Phenotype in an In Vitro Model of Hepatocellular Carcinoma. <i>Biomedicines</i> , 2021, 9, 1057.	3.2	2
155	Reverse time-dependent effect of alpha-fetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2017, 9, 1322-1331.	2.0	2
156	Braised Liver With Herbs: The Risks of Naturopathic Hepatoprotection. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, 344.	2.2	1
157	Fulminant liver failure caused by cyproterone. <i>Digestive and Liver Disease</i> , 2005, 37, 718-719.	0.9	1
158	Eighteen needles to forget: an unnamed past. <i>Journal of Clinical Forensic and Legal Medicine</i> , 2007, 14, 304-306.	1.0	1
159	Thromboembolism and breast cancer: the hidden risk for patient and physician. <i>Internal Medicine Journal</i> , 2007, 37, 133-134.	0.8	1
160	DECOMPRESSION SICKNESS IN A SEA-HEDGEHOG DIVER. <i>European Journal of Internal Medicine</i> , 2008, 19, S50.	2.2	1
161	PS-205-Longitudinal prognostic value of the most common algorithms for fibrosis in non-alcoholic fatty liver disease: An international study in non-cirrhotic, biopsy-proven patients. <i>Journal of Hepatology</i> , 2019, 70, e136-e137.	3.7	1
162	Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach. <i>World Journal of Gastroenterology</i> , 2017, 23, 3195.	3.3	1

#	ARTICLE	IF	CITATIONS
163	13C-methacetin breath test in patients with nonalcoholic steatohepatitis. Gastroenterology, 2000, 118, A974.	1.3	0
164	Quantitative liver function tests to assess MEHOS activity in NASH patients. Digestive and Liver Disease, 2001, 33, A57.	0.9	0
165	Fibrogenesis in non alcoholic steatohepatth (NASH). Digestive and Liver Disease, 2001, 33, A61.	0.9	0
166	Assessment of aminopyrine and methacetin 13C-breath tests in HCV-related chronic liver disease. Journal of Hepatology, 2002, 36, 230.	3.7	0
167	TWO CASE REPORTS OF CHYLOTHORAX DUE TO LYMPHANGIOLEIOMYOMATOSIS. European Journal of Internal Medicine, 2008, 19, S56.	2.2	0
168	A giant calcified hepatic mass. Annals of Hepatology, 2013, 12, 822-823.	1.5	0
169	Rare <i>Atg7</i> Genetic Variants Predispose to Severe Fatty Liver Disease. SSRN Electronic Journal, 0, , .	0.4	0
170	The pathophysiology of gut-liver connection. , 2021, , 97-122.		0
171	Etiopathogenesis of NAFLD: Diet, Gut, and NASH. , 2020, , 73-95.		0
172	Multimodal sequential treatment for occluded TIPS: Case report and review of literature. Clinical and Molecular Hepatology, 2020, 26, 227-230.	8.9	0
173	Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. American Journal of Gastroenterology, 2003, 98, 2335-2336.	0.4	0